Tempus AI, Inc., a prominent healthcare technology company based in Chicago, Illinois, has recently experienced a shift in its investment landscape. The company, which operates under the Nasdaq exchange, specializes in providing advanced healthcare solutions through its Tempus platform. This platform integrates clinician desktops with laboratory diagnostics, analytics, and a repository of multimodal data, facilitating a closed-loop, full-stack, bi-directional system. Additionally, Tempus AI offers the Hub, a clinical application designed for healthcare providers, and Lens, a software application for life sciences and precision research.
Tempus AI’s product line extends to diagnostics services, including Next-Generation Sequencing (NGS) diagnostics, PCR profiling, and various anatomic and molecular pathology tests. The company’s core clinical assays, xT and xR, provide comprehensive DNA and RNA analysis through blood or saliva samples. Furthermore, Tempus AI offers genetic tests for inherited conditions and an nP assay for pharmacogenomic testing, particularly for psychiatric conditions such as depression and anxiety.
The company’s strategic collaborations include partnerships with major pharmaceutical companies like AstraZeneca AB, GlaxoSmithKline, and Merck, as well as Blood Cancer United, focusing on developing a registry for pediatric acute myeloid leukemia. Tempus AI, formerly known as Tempus Labs, Inc., was incorporated in 2015 and rebranded in January 2023.
Recent market activity has seen Cathie Wood’s ARK Invest adjust its positions, reducing its holdings in Tempus AI. This decision followed a modest increase in Tempus AI’s stock price, attributed to a positive Phase 3 trial announcement. Analysts have assigned a moderate buy rating to the company, suggesting limited upside potential at current levels. ARK’s strategy appears to focus on balancing high-growth tech investments with more established healthcare entities.
As of September 3, 2026, Tempus AI’s stock closed at $64.62, with a 52-week high of $104.32 and a low of $40.77. The company’s market capitalization stands at approximately $11.66 billion. Despite the recent sale by ARK Invest, no further operational updates from Tempus AI have been disclosed.
